ACC 2022 | FLAVOUR Study: FFR and IVUS in Intermediate Coronary Lesions

FLAVOUR was a prospective randomized non-inferiority study in patients with intermediate coronary lesions (40%-70%) that compared two imaging modalities: IVUS (intravascular imaging) and FFR (fractional flow reserve). 

ACC 2022

According to this research—presented at ACC 2022—, FFR-guided angioplasty was non-inferior to IVUS-guided angioplasty at 2 years of follow-up. Furthermore, using FFR-based imaging led to fewer stent implantations.

A total of 1682 patients with intermediate coronary lesions were enrolled and divided into two groups: 838 were assigned to the FFR group, and 844 to the IVUS group.

The indication for coronary angioplasty included an FFR ≤0.80 and, for the IVUS group, a minimal luminal area ≤3 mm2 or a minimal luminal area >3 mm2 but ≤4 mm2 plus a plaque border >70%.

In the FFR group, only 44.4% of patients underwent coronary angioplasty compared with 65.3% in the IVUS group (p < 0.001).

The primary endpoint (PEP) was a composite of all-cause mortality, myocardial infarction, and any revascularization at 24 months. In that sense, the PEP occurred in 8.6% vs 8.1% for IVUS and FFR, respectively (pnon-inferiority = 0.015; margin of non-inferiority: 2.5%).

Read also: ACC 2022 | CLASP TR Study: Tricuspid Valve Repair with the PASCAL Device.

Furthermore, there were no differences regarding events analyzed separately between the two groups, nor was the presence of angina observed in the Seattle Angina Questionnaire scores.

There was a lower tendency towards stenting in the FFR group.

There was also no difference between groups in patients who received medical treatment.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the editorial board in SOLACI.org .


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...